产品和服务 / 产品类型 / 重组蛋白 / 生物标志物 & CD分子

Biotinylated Recombinant Human IGF1R/CD221 Protein (RP02386B)

Biotinylated Human IGF1R on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

The purity of Biotinylated Human IGF1R is greater than 95% as determined by SEC-HPLC.

Immobilized Anti-IGF1R Antibody at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human IGF1R, His Tag with the EC50 of 48.0ng/ml determined by ELISA.

All(3)|
货号: RP02386B
促销价:   ¥5250
货    期:在线咨询货期
抗体定制服务咨询 |
商城订购

详细信息

种属
Human
表达宿主
HEK293 cells
Calculated MW
105.8, 23 kDa
Observed MW
110-120, 52-55 kDa
标签
C-His&Avi
纯度
> 95% by Tris-Bis PAGE;> 95% by SEC-HPLC
内毒素
< 1 EU/μg of the protein by LAL method.
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
描述
Biotinylated Recombinant Human IGF1R/CD221 Protein is produced by Expi293 expression system. The target protein is expressed with sequence (Met1-Asn932 ) of Human IGF1R fused with a His tag and Avi tag at the C-terminal.
储存
Store at -20℃. Store the lyophilized protein at -20℃ to -80℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月;
复溶之后,蛋白溶液在-20°C及以下可保存3个月,在2-8℃可保存1周。
复溶
Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底,如果粉末浮起,开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL(请注意蛋白复溶浓度不能低于0.1 mg/mL),室温平衡5-10 min保证充分溶解,复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存,建议复溶时添加载体蛋白或者稳定剂(如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖),同时将复溶后的蛋白溶液按照需求进行分装,储存于-20°C至-80°C,随取随用,避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度,快速计算您需要添加溶液的体积吧!
=
÷

客户数据及评论 (0)

折叠内容

背景信息

The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.

>